| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.ABB.2003.08.013 |
| P953 | full work available at URL | https://api.elsevier.com/content/article/PII:S0003986103004399?httpAccept=text/plain |
| https://api.elsevier.com/content/article/PII:S0003986103004399?httpAccept=text/xml | ||
| P698 | PubMed publication ID | 14568006 |
| P50 | author | Paul J Thornalley | Q56810389 |
| P2860 | cites work | American Journal of Physiology | Q2160146 |
| Cellular and Molecular Biology | Q15749453 | ||
| Protein glycosylation and advanced glycosylated endproducts (AGEs) accumulation: an avian solution? | Q23918618 | ||
| Biochemistry and molecular cell biology of diabetic complications | Q28131781 | ||
| Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin | Q28185699 | ||
| Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals | Q28328519 | ||
| Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage | Q29616101 | ||
| Diabetic retinopathyA clinical update | Q30875448 | ||
| Mechanisms underlying endothelial dysfunction in diabetes mellitus | Q31829307 | ||
| Renoprotective effects of a novel inhibitor of advanced glycation | Q32019989 | ||
| Oxidative DNA damage induced by high glucose and its suppression in human umbilical vein endothelial cells | Q34086946 | ||
| Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking | Q34180583 | ||
| Early cellular and molecular changes induced by diabetes in the retina | Q34338727 | ||
| The glyoxalase system in health and disease | Q34347556 | ||
| Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats | Q34352122 | ||
| Discordant effects of guanidines on renal structure and function and on regional vascular dysfunction and collagen changes in diabetic rats | Q71909295 | ||
| Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model | Q72053237 | ||
| The reaction of d-glucose with aminoguanidine | Q72112610 | ||
| Toxicity of mildly modified low-density lipoproteins to cultured retinal capillary endothelial cells and pericytes | Q72150719 | ||
| Aminoguanidine does not inhibit the initial phase of experimental diabetic retinopathy in rats | Q72258248 | ||
| Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat | Q72345792 | ||
| Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction | Q72387391 | ||
| The effect of aminoguanidine and tolrestat on glucose toxicity in bovine retinal capillary pericytes | Q72462727 | ||
| Aminoguanidine: a drug proposed for prophylaxis in diabetes inhibits catalase and generates hydrogen peroxide in vitro | Q72547279 | ||
| The pharmacokinetics of aminoguanidine in end-stage renal disease patients on hemodialysis | Q72582677 | ||
| Effects of aminoguanidine on insulin release from pancreatic islets | Q72782649 | ||
| Effects of aminoguanidine on serum advanced glycation endproducts, urinary albilmin excretion, mesangial expansion, and glomerular basement membrane thickening in Otsuka Long-Evans Tokushima fatty rats | Q73153631 | ||
| Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C | Q73313410 | ||
| Functional and structural abnormalities in the nerves of type I diabetic baboons: aminoguanidine treatment does not improve nerve function | Q73443357 | ||
| AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells | Q73634250 | ||
| Efficient scavenging of fatty acid oxidation products by aminoguanidine | Q73664088 | ||
| Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats | Q73829192 | ||
| Aminoguanidine inhibits semicarbazide-sensitive amine oxidase activity: implications for advanced glycation and diabetic complications | Q73922976 | ||
| In vivo formation of a Schiff base of aminoguanidine with pyridoxal phosphate | Q74674415 | ||
| Diabetic nephropathy: prevention and treatment | Q77155189 | ||
| Aminoguanidine inhibits albuminuria, but not the formation of advanced glycation end-products in skin collagen of diabetic rats | Q77379022 | ||
| Potential benefit of inhibitors of advanced glycation end products in the progression of type II diabetes: a study with aminoguanidine in C57/BLKsJ diabetic mice | Q77730593 | ||
| Depletion of nitric oxide synthase-containing neurons in the diabetic retina: reversal by aminoguanidine | Q77731024 | ||
| Chronic aminoguanidine attenuates renal dysfunction and injury in aging rats | Q77795012 | ||
| Effect of aminoguanidine on lipid peroxidation in streptozotocin-induced diabetic rats | Q78251590 | ||
| Advanced glycation end products and the progressive course of renal disease. | Q34384751 | ||
| Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic Rat | Q34762247 | ||
| Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options | Q34800437 | ||
| Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency | Q35788419 | ||
| Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy | Q35805813 | ||
| Aminoguanidine and the prevention of leukocyte dysfunction in diabetes mellitus: a direct vital microscopic study | Q36893420 | ||
| Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. | Q37623293 | ||
| Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy | Q37653146 | ||
| Hyperglycemic pseudohypoxia and diabetic complications. | Q40908737 | ||
| Aminoguanidine supplementation delays the onset of senescence in vitro in dermal fibroblast-like cells from senescence-accelerated mice | Q40933376 | ||
| Accumulation of alpha-oxoaldehydes during oxidative stress: a role in cytotoxicity | Q40940923 | ||
| DNA modification in vivo by derivatives of glucose: enhancement by glutathione depletion | Q41711793 | ||
| Comparison of antioxidant activities of aminoguanidine, methylguanidine and guanidine by luminol-enhanced chemiluminescence | Q41897633 | ||
| Chromatographic assay of glycation adducts in human serum albumin glycated in vitro by derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and intrinsic fluorescence | Q42157623 | ||
| The reaction of methylglyoxal with aminoguanidine under physiological conditions and prevention of methylglyoxal binding to plasma proteins. | Q42282865 | ||
| Advanced glycation end-products are responsible for the impairment of corpus cavernosal smooth muscle relaxation seen in diabetes | Q43543923 | ||
| Ramipril and aminoguanidine restore renal lysosomal processing in streptozotocin diabetic rats | Q43554898 | ||
| alpha-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia | Q43584213 | ||
| Glycation cross-links inhibit matrix metalloproteinase-2 activation in vascular smooth muscle cells cultured on collagen lattice | Q43611279 | ||
| Glucose and palmitic acid induce degeneration of myofibrils and modulate apoptosis in rat adult cardiomyocytes | Q43719975 | ||
| Effect of chronic aminoguanidine treatment on age-related glycation, glycoxidation, and collagen cross-linking in the Fischer 344 rat. | Q43721293 | ||
| Chelating activity of advanced glycation end-product inhibitors | Q43777338 | ||
| The effects of aminoguanidine on renal changes in a baboon model of Type 1 diabetes | Q44070319 | ||
| Aminoguanidine pyridoxal adduct is superior to aminoguanidine for preventing diabetic nephropathy in mice | Q44110310 | ||
| Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy | Q44195281 | ||
| ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. | Q44195285 | ||
| Effects of inhibition of glycation and oxidative stress on the development of diabetic nephropathy in rats | Q44245954 | ||
| Effect of dietary aminoguanidine on tissue pentosidine and reproductive performance in broiler breeder hens | Q45107517 | ||
| Formation of reactive intermediates from Amadori compounds under physiological conditions | Q47632318 | ||
| Effect of aminoguanidine on optic nerve involvement in experimental diabetic rats | Q47759542 | ||
| Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis | Q47904015 | ||
| The nitric oxide hypothesis of aging | Q48287971 | ||
| Kinetics and mechanism of the reaction of aminoguanidine with the alpha-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions. | Q52078784 | ||
| Age-dependent accumulation of advanced glycation end-products in adult Drosophila melanogaster. | Q52563298 | ||
| Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). | Q53540821 | ||
| Rapid induction of messenger RNA for nitric oxide synthase II in rat neutrophils in vivo by endotoxin and its suppression by prednisolone. | Q54639650 | ||
| Nitric oxide synthases: structure, function and inhibition | Q55951119 | ||
| Effects of heparin and aminoguanidine on glomerular basement membrane thickening in diabetic rats | Q60724001 | ||
| Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatization by 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and application to N∊-carboxymethyl-lysine- and N∊-(1-carboxyethyl)lysine-modified albu | Q60786605 | ||
| The reaction of some dicarbonyl sugars with aminoguanidine | Q67573548 | ||
| Aminoguanidine treatment reduces the increase in collagen stability of rats with experimental diabetes mellitus | Q68065335 | ||
| 3-Deoxy-L-glycero-pentos-2-ulose (3-deoxy-L-xylosone) and L-threo-pentos-2-ulose (L-xylosone) as intermediates in the degradation of L-ascorbic acid | Q70265291 | ||
| Aminoguanidine inhibits protein browning without extensive Amadori carbonyl blocking | Q70658685 | ||
| Effect of aminoguanidine on the frequency of neuroaxonal dystrophy in the superior mesenteric sympathetic autonomic ganglia of rats with streptozocin-induced diabetes | Q70983840 | ||
| Inhibition of cataracts in moderately diabetic rats by aminoguanidine | Q71402808 | ||
| Aminoguanidine is an isoform-selective, mechanism-based inactivator of nitric oxide synthase | Q71671331 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biochemistry | Q7094 |
| biophysics | Q7100 | ||
| P1104 | number of pages | 10 | |
| P304 | page(s) | 31-40 | |
| P577 | publication date | 2003-11-01 | |
| P1433 | published in | Archives of Biochemistry and Biophysics | Q635818 |
| P1476 | title | Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts | |
| P478 | volume | 419 |
| Q48274280 | 6-Nitroazolo[1,5-a]pyrimidin-7(4H)-ones as Antidiabetic Agents. |
| Q38197363 | A fluorogenic assay for methylglyoxal |
| Q35746724 | A global perspective of the genetic basis for carbonyl stress resistance |
| Q38847549 | A synopsis on aging-Theories, mechanisms and future prospects |
| Q38785141 | Actein protects against methylglyoxal-induced oxidative damage in osteoblastic MC3T3-E1 cells |
| Q37149382 | Advanced glycation end products and diabetic foot disease |
| Q37429192 | Advanced glycation end products in extracellular matrix proteins contribute to the failure of sensory nerve regeneration in diabetes |
| Q37006353 | Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications |
| Q38118993 | Advanced glycation end-products: a common pathway in diabetes and age-related erectile dysfunction |
| Q36887564 | Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors. |
| Q51016965 | Aegle marmelos Correa leaf extract prevents secondary complications in streptozotocin-induced diabetic rats and demonstration of limonene as a potent antiglycating agent. |
| Q35409645 | Age-related vascular stiffening: causes and consequences. |
| Q36370381 | Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health |
| Q36265726 | Amine oxidase substrates for impaired glucose tolerance correction. |
| Q37127122 | Aminoguanidine impedes human pancreatic tumor growth and metastasis development in nude mice. |
| Q33611742 | Aminoguanidine inhibits aortic hydrogen peroxide production, VSMC NOX activity and hypercontractility in diabetic mice |
| Q42010611 | Aminoguanidine partially prevents the reduction in liver pyruvate kinase activity in diabetic rats |
| Q36052796 | Aminoguanidine prevents fructose-induced deterioration in left ventricular-arterial coupling in Wistar rats. |
| Q36736336 | Aminoguanidine prevents the impairment of cardiac pumping mechanics in rats with streptozotocin and nicotinamide-induced type 2 diabetes |
| Q90402415 | Aminoguanidine reduces diabetes-associated cardiac fibrosis |
| Q42909616 | Aminoguanidine reduces oxidative stress and structural lung changes in experimental diabetes mellitus |
| Q45914599 | An aqueous pomegranate seed extract ameliorates oxidative stress of human hepatoma HepG2 cells. |
| Q38001410 | An update on advanced glycation endproducts and atherosclerosis |
| Q86810369 | Anti-glycation activities of phenolic constituents from Silybum marianum (Milk Thistle) flower in vitro and on human explants |
| Q93093146 | Anti-glycation, anti-hemolysis, and ORAC activities of demethylcurcumin and tetrahydroxycurcumin in vitro and reductions of oxidative stress in D-galactose-induced BALB/c mice in vivo |
| Q36556750 | Antiglycation Activity of Iridoids and Their Food Sources |
| Q52581941 | Antiglycation and antioxidant activities of mogroside extract from Siraitia grosvenorii (Swingle) fruits. |
| Q40112278 | Antiglycation, radical scavenging, and semicarbazide-sensitive amine oxidase inhibitory activities of acetohydroxamic acid in vitro |
| Q45253199 | Antiglycative effect of fruit and vegetable seed extracts: inhibition of AGE formation and carbonyl-trapping abilities. |
| Q21254685 | Antioxidant, antiglycation and cytotoxicity evaluation of selected medicinal plants of the Mascarene Islands |
| Q30431517 | Apolipoprotein A-I glycation by glucose and reactive aldehydes alters phospholipid affinity but not cholesterol export from lipid-laden macrophages |
| Q64250805 | Baijiu Vinasse Extract Scavenges Glyoxal and Inhibits the Formation of -Carboxymethyllysine in Dairy Food |
| Q38232036 | Baking, ageing, diabetes: a short history of the Maillard reaction |
| Q36495879 | Beneficial effects of aminoguanidine on skin flap survival in diabetic rats |
| Q92328576 | Biosynthesized ZnO-NPs from Morus indica Attenuates Methylglyoxal-Induced Protein Glycation and RBC Damage: In-Vitro, In-Vivo and Molecular Docking Study |
| Q88496393 | Buckwheat bioactive compounds, their derived phenolic metabolites and their health benefits |
| Q34334665 | Carbonylation of myosin heavy chains in rat heart during diabetes |
| Q90218719 | Cationic Arginine-Rich Peptides (CARPs): A Novel Class of Neuroprotective Agents With a Multimodal Mechanism of Action |
| Q35766899 | Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications |
| Q39973851 | Chitosan Prevents Gentamicin-Induced Nephrotoxicity via a Carbonyl Stress-Dependent Pathway |
| Q42613872 | Cinnamic acid and its derivatives inhibit fructose-mediated protein glycation |
| Q35946117 | Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease |
| Q34591116 | Combination of Medicinal Herbs KIOM-79 Reduces Advanced Glycation End Product Accumulation and the Expression of Inflammatory Factors in the Aorta of Zucker Diabetic Fatty Rats |
| Q37193283 | Crystal structure of bis-{4-bromo-2-[(carb-amim-id-amido-imino)-meth-yl]phenolato-κ(3) N,N',O}cobalt(III) nitrate di-methyl-formamide monosolvate. |
| Q37058905 | Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications |
| Q38070906 | Current therapeutic interventions in the glycation pathway: evidence from clinical studies |
| Q39140722 | Cytotoxicity of 1,4-diamino-2-butanone, a putrescine analogue, to RKO cells: mechanism and redox imbalance |
| Q30013723 | DFT study of the mechanism of the reaction of aminoguanidine with methylglyoxal |
| Q38620860 | Damaging effects of hyperglycemia on cardiovascular function: spotlight on glucose metabolic pathways |
| Q38815690 | Development of a neuroprotective potential algorithm for medicinal plants. |
| Q28086840 | Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets |
| Q34387952 | Diabetic nephropathy - complications and treatment |
| Q33554384 | Diabetic neuropathy: mechanisms to management |
| Q35670859 | Dietary advanced glycation end products and aging |
| Q39725004 | Dietary phenolic acids attenuate multiple stages of protein glycation and high-glucose-stimulated proinflammatory IL-1beta activation by interfering with chromatin remodeling and transcription in monocytes |
| Q33538479 | Discovery of rifampicin as a new anti-glycating compound by matrix-assisted laser desorption/ionization mass spectrometry-based insulin glycation assay |
| Q27322912 | Edaravone protects against methylglyoxal-induced barrier damage in human brain endothelial cells |
| Q33787882 | Effect of cranberry (Vaccinium macrocarpon) oligosaccharides on the formation of advanced glycation end-products |
| Q50970272 | Effect of fermented and unfermented buckwheat flour on functional properties of gluten-free muffins. |
| Q38967561 | Effects of curcumin in experimental diabetic nephropathy |
| Q34068791 | Ellagic acid, a new antiglycating agent: its inhibition of Nϵ-(carboxymethyl)lysine. |
| Q33785681 | Endotoxin mediated-iNOS induction causes insulin resistance via ONOO⁻ induced tyrosine nitration of IRS-1 in skeletal muscle |
| Q51131271 | Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds. |
| Q46235331 | Estrogen deficiency-induced alterations of vascular MMP-2, MT1-MMP, and TIMP-2 in ovariectomized rats. |
| Q37959165 | Evolution of treatment for diabetic nephropathy: historical progression from RAAS inhibition and onward |
| Q36913552 | Glucitol-core containing gallotannins inhibit the formation of advanced glycation end-products mediated by their antioxidant potential |
| Q38062900 | Glycated proteome: from reaction to intervention |
| Q37054987 | Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complicat |
| Q46678945 | Glycation free adduct accumulation in renal disease: the new AGE. |
| Q92017934 | Glycation in Huntington's Disease: A Possible Modifier and Target for Intervention |
| Q24608214 | Glycation of LDL by methylglyoxal increases arterial atherogenicity: a possible contributor to increased risk of cardiovascular disease in diabetes |
| Q46007995 | Glycation of aspartate aminotransferase by methylglyoxal, effect of hydroxycitric and uric acid. |
| Q46425686 | Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation |
| Q37803550 | Glycation research in amino acids: a place to call home |
| Q39096507 | Glycative Stress and Its Defense Machinery Glyoxalase 1 in Renal Pathogenesis |
| Q95828462 | Healthy Eating Recommendations: Good for Reducing Dietary Contribution to the Body's Advanced Glycation/Lipoxidation End Products Pool? |
| Q45988063 | Hepatocyte inflammation model for cytotoxicity research: fructose or glycolaldehyde as a source of endogenous toxins. |
| Q38616124 | Hormesis enables cells to handle accumulating toxic metabolites during increased energy flux |
| Q90362741 | Human Copper-Containing Amine Oxidases in Drug Design and Development |
| Q40319157 | Hydrazine compounds inhibit glycation of low-density lipoproteins and prevent the in vitro formation of model foam cells from glycolaldehyde-modified low-density lipoproteins. |
| Q36900791 | Hyperglycemic oxoaldehyde, glyoxal, causes barrier dysfunction, cytoskeletal alterations, and inhibition of angiogenesis in vascular endothelial cells: aminoguanidine protection. |
| Q39708396 | Imidazopurinones are markers of physiological genomic damage linked to DNA instability and glyoxalase 1-associated tumour multidrug resistance |
| Q39368611 | Impact of Non-Enzymatic Glycation in Neurodegenerative Diseases: Role of Natural Products in Prevention. |
| Q58775747 | Improved Methods for the Rapid Formation and Prevention of Advanced Glycation End Products (AGEs) In Vitro by Coupling to the Hypoxanthine/Xanthine Oxidase Assay System |
| Q64069141 | Improvement in Diabetic Retinopathy through Protection against Retinal Apoptosis in Spontaneously Diabetic Torii Rats Mediated by Ethanol Extract of C.K. Schneid |
| Q36181550 | In vitro inhibitory activities of selected Australian medicinal plant extracts against protein glycation, angiotensin converting enzyme (ACE) and digestive enzymes linked to type II diabetes |
| Q89857321 | Inactive matrix gla protein plasma levels are associated with peripheral neuropathy in Type 2 diabetes |
| Q54185478 | Increased peritoneal damage in glyoxalase 1 knock-down mice treated with peritoneal dialysis. |
| Q46613224 | Increased protein glycation in cirrhosis and therapeutic strategies to prevent it. |
| Q46531143 | Inhibition of Advanced Glycation End-Product Formation and Antioxidant Activity by Extracts and Polyphenols from Scutellaria alpina L. and S. altissima L. |
| Q34816148 | Inhibition of advanced glycation end products by red grape skin extract and its antioxidant activity |
| Q46923416 | Inhibitors of advanced glycation end-products prevent loss of enteric neuronal nitric oxide synthase in diabetic rats |
| Q36149136 | Inhibitory actions of selected natural substances on formation of advanced glycation endproducts and advanced oxidation protein products |
| Q46418357 | Inhibitory activities of prenylated flavonoids from Sophora flavescens against aldose reductase and generation of advanced glycation endproducts |
| Q35607690 | Inhibitory effect of Clitoria ternatea flower petal extract on fructose-induced protein glycation and oxidation-dependent damages to albumin in vitro |
| Q35487583 | Inhibitory effect of gold nanoparticles on the D-ribose glycation of bovine serum albumin |
| Q34983879 | Inhibitory effect of metformin and pyridoxamine in the formation of early, intermediate and advanced glycation end-products |
| Q41265686 | Jakyakgamcho-tang and Its Major Component, Paeonia Lactiflora, Exhibit Potent Anti-glycation Properties |
| Q35133347 | KIOM-79, an Inhibitor of AGEs-Protein Cross-linking, Prevents Progression of Nephropathy in Zucker Diabetic Fatty Rats |
| Q42756908 | Limited joint mobility in diabetes and ageing: recent advances in pathogenesis and therapy |
| Q26798973 | Limited joint mobility syndrome in diabetes mellitus: A minireview |
| Q26795694 | Linking RAGE and Nox in diabetic micro- and macrovascular complications |
| Q36568547 | Lipoxidation-derived reactive carbonyl species as potential drug targets in preventing protein carbonylation and related cellular dysfunction |
| Q35811824 | Low-molecular-weight chitosan scavenges methylglyoxal and N (ε)-(carboxyethyl)lysine, the major factors contributing to the pathogenesis of nephropathy. |
| Q36485424 | Malondialdehyde and 4-hydroxynonenal adducts are not formed on cardiac ryanodine receptor (RyR2) and sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA2) in diabetes |
| Q36851848 | Management of limited joint mobility in diabetic patients |
| Q38096444 | Molecular strategies to prevent, inhibit, and degrade advanced glycoxidation and advanced lipoxidation end products. |
| Q58870482 | Natural inhibitors of advanced glycation end‐products |
| Q37903708 | Naturally occurring inhibitors against the formation of advanced glycation end-products |
| Q30235132 | New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain |
| Q35650520 | New knowledge on the antiglycoxidative mechanism of chlorogenic acid. |
| Q37070946 | Novel insights in the treatment of diabetic nephropathy. |
| Q61454663 | Nutritional and Pharmacological Effects on Oxidative Stress in Soft Tissue and Bone Remodeling |
| Q36120275 | Nutritional supplements modulate fluorescent protein-bound advanced glycation endproducts and digestive enzymes related to type 2 diabetes mellitus |
| Q42083685 | OSSC1E-K19, a novel phytochemical component of Osteomeles schwerinae, prevents glycated albumin-induced retinal vascular injury in rats |
| Q38473579 | Oxidation as an important factor of protein damage: Implications for Maillard reaction. |
| Q38216061 | Oxidative stress, protein glycation and nutrition--interactions relevant to health and disease throughout the lifecycle. |
| Q35684097 | Oxidized LDL and Fructosamine Associated with Severity of Coronary Artery Atherosclerosis in Insulin Resistant Pigs Fed a High Fat/High NaCl Diet |
| Q34137628 | Pathological aspects of lipid peroxidation. |
| Q41265617 | Pectin lyase-modified red ginseng extract exhibits potent anti-glycation effects in vitro and in vivo |
| Q36770323 | Pharmacological neuroprotection for glaucoma |
| Q37858519 | Pharmacological treatment of diabetic neuropathic pain |
| Q35261440 | Pomegranate phenolics inhibit formation of advanced glycation endproducts by scavenging reactive carbonyl species |
| Q36204035 | Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design |
| Q35683751 | Preconditioning L6 Muscle Cells with Naringin Ameliorates Oxidative Stress and Increases Glucose Uptake |
| Q26751110 | Prevention of non-enzymatic glycosylation (glycation): Implication in the treatment of diabetic complication |
| Q38358965 | Prevention of protein glycation by natural compounds. |
| Q43167963 | Preventive effects of taurine against d-galactose-induced cognitive dysfunction and brain damage |
| Q41680141 | Protective activity of gallic acid against glyoxal -induced renal fibrosis in experimental rats |
| Q28248107 | Protein carbonylation, cellular dysfunction, and disease progression |
| Q28295637 | Protein glycation inhibitors from the fruiting body of Phellinus linteus |
| Q37499860 | Reduction of advanced-glycation end products levels and inhibition of RAGE signaling decreases rat vascular calcification induced by diabetes |
| Q35600193 | Resorcylidene aminoguanidine (RAG) improves cardiac mitochondrial bioenergetics impaired by hyperglycaemia in a model of experimental diabetes |
| Q45918596 | Resorcylidene aminoguanidine induces antithrombotic action that is not dependent on its antiglycation activity. |
| Q36065113 | Retinylamine Benefits Early Diabetic Retinopathy in Mice |
| Q64983576 | Role of Apple Phytochemicals, Phloretin and Phloridzin, in Modulating Processes Related to Intestinal Inflammation. |
| Q37370688 | Role of advanced glycation end products with oxidative stress in resistance artery dysfunction in type 2 diabetic mice |
| Q53620385 | Scopoletin protects against methylglyoxal-induced hyperglycemia and insulin resistance mediated by suppression of advanced glycation endproducts (AGEs) generation and anti-glycation. |
| Q37407974 | Structure-activity relationships of SSAO/VAP-1 arylalkylamine-based substrates |
| Q35376455 | Sub-antimicrobial doxycycline for periodontitis reduces hemoglobin A1c in subjects with type 2 diabetes: a pilot study |
| Q46081402 | Suppression of retinal neovascularization by the iNOS inhibitor aminoguanidine in mice of oxygen-induced retinopathy |
| Q48298548 | Synthesis and Evaluation of Novel [1,2,4]Triazolo[5,1-c][1,2,4]-triazines and Pyrazolo[5,1-c][1,2,4]triazines as Potential Antidiabetic Agents |
| Q35619034 | Systems biology of kidney diseases |
| Q38890348 | Targeting advanced glycation with pharmaceutical agents: where are we now? |
| Q37066216 | The action of aminoguanidine on the liver of trained diabetic rats |
| Q56760512 | The aldo-keto reductase superfamily and its role in drug metabolism and detoxification |
| Q36942530 | The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes |
| Q47549644 | The effect of aminoguanidine (AG) and pyridoxamine (PM) on ageing human cortical bone |
| Q50548113 | The effects of long-term storage of human red blood cells on the glutathione synthesis rate and steady-state concentration. |
| Q36181533 | The ethyl acetate fraction of corn silk exhibits dual antioxidant and anti-glycation activities and protects insulin-secreting cells from glucotoxicity |
| Q30372854 | The hydrolyzable gallotannin, penta-O-galloyl-β-D-glucopyranoside, inhibits the formation of advanced glycation endproducts by protecting protein structure. |
| Q38848764 | The pecking order of skin Advanced Glycation Endproducts (AGEs) as long-term markers of glycemic damage and risk factors for micro- and subclinical macrovascular disease progression in Type 1 diabetes |
| Q35756294 | The production of cross-reactive autoantibodies that bind to bovine serum albumin in mice administered reducing sugars by subcutaneous injection |
| Q38778865 | The protective effects of pomelo extract (Citrus grandis L. Osbeck) against fructose-mediated protein oxidation and glycation |
| Q38241689 | The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach |
| Q42378770 | The role of glycation in the pathogenesis of aging and its prevention through herbal products and physical exercise |
| Q37044976 | The roles of hyperglycaemia and oxidative stress in the rise and collapse of the natural protective mechanism against vascular endothelial cell dysfunction in diabetes |
| Q38077549 | Therapeutic potential of targeting lipid aldehydes and lipoxidation end-products in the treatment of ocular disease. |
| Q42499319 | Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation |
| Q46931461 | Transmission electron microscopy and autofluorescence findings in the cornea of diabetic rats treated with aminoguanidine |
| Q30352122 | Twenty-five years since the discovery of endothelium-derived relaxing factor (EDRF): does a dysfunctional endothelium contribute to the development of type 2 diabetes? |
| Q44916007 | Unexpected elevation of pentosidine formation in collagen incubated with glucose by low concentrations of the AGE-inhibitor aminoguanidine |
Search more.